ALK-Abelló A/S (ALK-B) - Total Assets
Based on the latest financial reports, ALK-Abelló A/S (ALK-B) holds total assets worth Dkr9.17 Billion DKK (≈ $1.44 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ALK-Abelló A/S - Total Assets Trend (2005–2025)
This chart illustrates how ALK-Abelló A/S's total assets have evolved over time, based on quarterly financial data. Also see ALK-B market cap for the company's overall valuation and market capitalisation.
ALK-Abelló A/S - Asset Composition Analysis
Current Asset Composition (December 2025)
ALK-Abelló A/S's total assets of Dkr9.17 Billion consist of 49.0% current assets and 51.0% non-current assets. Review debt load of ALK-Abelló A/S to assess the company's total debt and financial obligations.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 13.5% |
| Accounts Receivable | Dkr1.34 Billion | 14.6% |
| Inventory | Dkr1.78 Billion | 19.4% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr1.31 Billion | 14.3% |
| Goodwill | Dkr455.00 Million | 5.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how ALK-Abelló A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ALK-B share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ALK-Abelló A/S's current assets represent 49.0% of total assets in 2025, a decrease from 87.6% in 2005.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, down from 80.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 2.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 19.4% of total assets.
ALK-Abelló A/S Competitors by Total Assets
Key competitors of ALK-Abelló A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
ALK-Abelló A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.38 | 1.69 | 2.33 |
| Quick Ratio | 2.04 | 0.81 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr3.17 Billion | Dkr1.34 Billion | Dkr1.44 Billion |
ALK-Abelló A/S - Advanced Valuation Insights
This section examines the relationship between ALK-Abelló A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.72 |
| Latest Market Cap to Assets Ratio | 0.66 |
| Asset Growth Rate (YoY) | 11.2% |
| Total Assets | Dkr9.17 Billion |
| Market Capitalization | $6.06 Billion USD |
Valuation Analysis
Below Book Valuation: The market values ALK-Abelló A/S's assets below their book value (0.66x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ALK-Abelló A/S's assets grew by 11.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ALK-Abelló A/S (2005–2025)
The table below shows the annual total assets of ALK-Abelló A/S from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr9.17 Billion ≈ $1.44 Billion |
+11.23% |
| 2024-12-31 | Dkr8.25 Billion ≈ $1.29 Billion |
+22.60% |
| 2023-12-31 | Dkr6.73 Billion ≈ $1.05 Billion |
+6.63% |
| 2022-12-31 | Dkr6.31 Billion ≈ $986.93 Million |
+8.20% |
| 2021-12-31 | Dkr5.83 Billion ≈ $912.15 Million |
+4.80% |
| 2020-12-31 | Dkr5.56 Billion ≈ $870.37 Million |
+1.24% |
| 2019-12-31 | Dkr5.50 Billion ≈ $859.73 Million |
+12.95% |
| 2018-12-31 | Dkr4.87 Billion ≈ $761.16 Million |
-1.88% |
| 2017-12-31 | Dkr4.96 Billion ≈ $775.72 Million |
+3.31% |
| 2016-12-31 | Dkr4.80 Billion ≈ $750.84 Million |
+12.86% |
| 2015-12-31 | Dkr4.25 Billion ≈ $665.26 Million |
+24.36% |
| 2014-12-31 | Dkr3.42 Billion ≈ $534.93 Million |
+4.62% |
| 2013-12-31 | Dkr3.27 Billion ≈ $511.30 Million |
-0.43% |
| 2012-12-31 | Dkr3.28 Billion ≈ $513.49 Million |
-2.15% |
| 2011-12-31 | Dkr3.35 Billion ≈ $524.76 Million |
+18.52% |
| 2010-12-31 | Dkr2.83 Billion ≈ $442.77 Million |
+6.67% |
| 2009-12-31 | Dkr2.65 Billion ≈ $415.08 Million |
+4.53% |
| 2008-12-31 | Dkr2.54 Billion ≈ $397.09 Million |
-10.03% |
| 2007-12-31 | Dkr2.82 Billion ≈ $441.37 Million |
+1.15% |
| 2006-12-31 | Dkr2.79 Billion ≈ $436.36 Million |
-59.67% |
| 2005-12-31 | Dkr6.92 Billion ≈ $1.08 Billion |
-- |
About ALK-Abelló A/S
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more